The new bis 4-bromobenzene sulphonate compound called as ((1E,1'E)-(1,4-phenylenebis(azanylylidene))bis(methanylylidene))bis(4,1-phenylene) bis(4-bromobenzenesulfonate) (I) was synthesized. Fourier transform infrared (FTIR), proton and carbon-13 nuclear magnetic resonance (1H- and 13C-NMR) methods were used to confirm the molecular structure. All calculations were performed at DFT/B3LYP/6-311G(d,p) level. IR and NMR spectral data were compared with experimental ones and the details of molecular structure were investigated. The antimicrobial activity of the synthesized compound (I) was determined by Alamar blue microdilution method against seven different established standard bacteria and one parasite isolate. The compound I exhibited antibacterial activity at different concentrations. Compound I was found to have antimicrobial activity on all bacterial species and L. infantum parasite, albeit at different concentrations. Compound I has the most effective antibacterial activity on S. flexneri and the least effect on S. aureus and E. cloacea bacteria. In order for the synthesized compound to be used as a drug candidate, in vivo control studies in a series of experimental animal models and whether it has toxic effects on human cells should be tested. In silico analysis was conducted on four different proteins using the synthesized compound I to investigate the essential interactions responsible for its antibacterial activity. The docking results of compound I supported its antibacterial activity, revealing high inhibition constants.
Read full abstract